U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
U.S. Dollar Slides for Second Week as Tariff Threats and Iran Tensions Shake Markets 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Oil Prices Hit Four-Month High as Geopolitical Risks and Supply Disruptions Intensify 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
